Compare Fox Corp Class B (FOX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs GeneDx Holdings Corp — how do they compare? Fox Corp Class B trades at $55.89 (market cap $25.36B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Fox Corp Class B is far larger — about 12.6× GeneDx Holdings Corp's market cap, and Fox Corp Class B pays a 1.02% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and GeneDx Holdings Corp for 19 Days on average.
| FOX | WGS | |
|---|---|---|
Market Cap | $25.36B | $2.02B |
Volume | 886,620 | 734,640 |
Sector | Media | Health |
52-Week High | $67.76 | $167.51 |
52-Week Low | $44.39 | $34.51 |
Typical Hold Time | 75 Days | 19 Days |
Enterprise Value | $28.72B | $2.05B |
Dividend Yield | 1.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX stock trades at $55.89, down 0.16% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.79 surpassing the $1.44 estimate. Revenue grew to $16.30 billion in 2025, and net income margin improved to 13.88%. Analysts maintain a consensus price target of $84.75, implying significant upside, with 42% recommending Buy.
The outlook is positive given earnings momentum and reasonable valuation multiples, but risks include projected net cash flow turning negative in 2026 and competitive pressures in media. Investor sentiment is supported by bullish analyst targets, though attention is needed on debt levels and future profitability trends.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
